Group 1 - The core viewpoint of the article is that Shandong Shengdi Pharmaceutical Co., Ltd. has initiated a Phase III clinical trial to evaluate the efficacy and safety of HRS-8080 in combination with Darsilid compared to Fulvestrant in patients with locally advanced or metastatic breast cancer who are resistant to prior endocrine therapy [1][2] - The clinical trial is registered under the number CTR20260083, with the first public information date set for January 14, 2026 [1] - The primary endpoint of the trial is progression-free survival (PFS) assessed by the investigator, while secondary endpoints include PFS assessed by BICR, overall response rate (ORR), clinical benefit rate (CBR), duration of response (DoR), overall survival (OS), and the incidence and severity of adverse events (AE) and serious adverse events (SAE) [1] Group 2 - The trial is currently ongoing and has not yet started recruiting participants, with a target enrollment of 912 individuals [2]
山东盛迪HRS - 8080片启动III期临床 适应症为乳腺癌
Xin Lang Cai Jing·2026-01-14 05:10